New GLP-1 Clinical Study Finds Calocurb Reduces Body Weight and Body Fat Without Loss of Muscle Mass The natural GLP-1 activator is clinically shown to support fat loss, including visceral fat reduction, while preserving lean muscle AUCKLAND, New Zealand, July 23, 2026 --(BUSINESS WIRE)--Calocurb, the New Zealand-based company bringing the world the first 100% natural GLP-1 activator, announces today the publication of a new clinical study in US medical journal, Obesity Pillars, demonstrating Calocurb's effectiveness in weight loss and muscle preservation
Two drugs, sirukumab and siltuximab, that directly target IL-6 ligands and block classical signaling and trans-signaling can be distinguished based on the inflammatory mechanism of CKD development
Peptides serve many functions in the body
Many studies had small sample sizes, and trial quality varied
Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin avb3
When to Contact Your Provider Mild symptoms such as temporary fatigue or injection irritation Monitor and discuss at follow-up Persistent bloating, appetite changes, or headaches Schedule a check-in Severe symptoms such as chest pain or allergic reactions Seek immediate medical care Questions to Ask Before Starting Ipamorelin Before starting ipamorelin, ask your provider: What side effects should I watch for
